12 tomas, Nr. 4 - Medicinos teorija ir praktika

discriminating between cardiac and non-cardiac
dyspnoea. Europ J Heart Failure. 2004;6:63-70.
10. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility
of B-type natriuretic peptide (BNP) in the diagnosis
of CHFin an urgent care setting. J Am Coll
Cardiol. 2001; 37:379-85.
11. McCullough PA, Nowak RM, McCord J, et al.
B-type natriuretic peptide and clinical judgment
in emergency diagnosis of heart failure: analysis
from Breathing Not Properly (BNP) Multinational
Study. Circulation. 2002; 106:416-22.
12. Bayes-Genis A, Santalo-Bel M, Zapico-Muniz
E, et al. N-terminal probrain natriuretic peptide
(NT-proBNP) in the emergency diagnosis and
in-hospital monitoring of patients with dyspnoea
and ventricular dysfunction. Europ J Heart Failure.
2004; 6:301-8.
13. Nagaya N, Nishikimi T, Okano Y, et al. Plasma
brain natriuretic peptide levels increase in proportion
to the extent of right ventriclar dysfunction
in pulmonary hypertension. J Am Coll Cardiol.
1998; 31:202-8.
14. Lainchbury JG, Campbell E, Frampton CM, et
al. Brain natriuretic peptide and N-terminal brain
natriuretic peptide in the diagnosis of heart failure
in patients with acute shortness of breath. J Am
Coll Cardiol. 2003; 42:728-35.
15. Pfister R, Scholz M, Wielckens K, et al. Use of
NT-proBNP in routine testing and comparison to
BNP. Europ J Heart Failure. 2004; 6:289-93.
16. Maisel AS, Hlavin P, McCord J et al. B-type natriuretic
peptide in the emergency diagnosis of
diastolic dysfunction heart failure [abstract]. J Am
Coll Cardiol. 2002; 39:140A.
17. Dahlstrőm U. Can natriuretic peptides be used
for the diagnosis of diastolic heart failure? Europ J
Heart Failure. 2004; 6:281-7.
18. Stanek B, Frey B, Hulsmann M, et al. Prognostic
evaluation of neurohormonal plasma levels before
and during beta-blockers therapy inadvanced left
ventricular dysfunction. J Am Coll Cardiol. 2001;
38:436-42.
19. Gardner RS, Özalp F, Murday AJ, et al. N-terminal
pro-brain natriuretic peptide. A new gold standart
in predicting mortality in patients with advanced
heart failure. Europ Heart J. 2003; 24:1735-43.
20. Hartman F, Packer M, Coats AJS, et al. NTproBNP
in severe chronic herat failure: rationale,
design and preliminary results of the COPERNI-
teorija ir praktika 2006 - T. 12 (Nr. 4)
apþvalgos
CUS NT-proBNP substudy. Europ J Heart Failure.
2004; 6:343-50.
21. Fischer C, Berry C, Blue L, et al. N-terminal pro
B-type natriuretic peptide, but not the new putative
cardiac hormone relaxin, predicts prognosis
in patients with chronic heart failure. Heart.
2003; 89:879-81.
22. Wu AHB, Smith A. Biological variation of the natriuretic
peptides and their role in the monitoring
patients with heart failure. Europ J Heart Failure.
2004; 6:355-8.
23. Troughton RW, Frampton CM, Yandle TG, et al.
Treatment of heart failure guided by plasma aminoterminal
brain natriuretic peptide (N-BNP)
concentration. Lancet. 2000; 355:1126-30.
24. Richards AM, Doughty R, Nicholls MG et al.
Plasma N-terminal pro-brain natriuretic peptide
and adrenomedullin: prognostic utility and prediction
of benefit from carvedilol in chronic ischemic
left ventricular dysfunction. Australia-New
Zealand Heart Failure Group. J Am Coll Cardiol.
2001; 37:1781-87.
25. Johnston N, Green M, Robb S, Morton I, Dargie
H. Tailoring beta-blockers therapy in patients
with chronic heart failure (abstract). J Am Coll
Cardiol. 2003; 41:144A.
26. Richards M, Troughton RW. NT-proBNP in heart
failure: therapy decisions and monitoring. Europ J
Heart Failure. 2004; 6:351-54.
27. Omland T, Aakvaag A, Bonarjee VV, et al. Plasma
brain natriuretic pepetide as an indicator of left
ventricular systolic funcion and long-term survival
after acute myocardial infaction. Comparison
with plasma atrial natriuretic peptide and N-terminal
proatrial natriuretic peptide. Circulation.
1996; 93:1963-69.
28. Arakawa N, Nakamura M, Aoki H, Hiramori K.
Plasma brain natriuretic peptide concentrations
predict survival after acute myocardial infarction.
J Am Coll Cardiol. 1996; 27:1656-61.
29. Darbar D, Davidson NC, Gillespie N, et al. Diagnostic
value of B-type natriuretic peptide concentration
in patients with acute myocardial infarction.
Am J Cardiol. 1996; 78:284-7.
30. Richards AM, Nicholls MG, Yandle TG, et al.
Plasma N-terminal pro-brain natriuretic peptide
and adrenomedullin: new neurohormonal predictors
of left ventricular function and prognosis
after myocardial infarction. Circulation. 1998;
97:1921-9.
291